Lung Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Lung Cancer, including details on symptoms, smoking, genetics, treatment, causes.

Volume 2 (2005), Issue 12 (December)

1. Lung cancer risks in relation to vegetable and fruit consumption and smoking.
   Int J Cancer, 118(3): 739-43. [Abstract] [Full-text]
2. Polymorphism of Xeroderma Pigmentosum group G and the risk of lung cancer and squamous cell carcinomas of the oropharynx, larynx and esophagus.
   Int J Cancer, 118(3): 714-20. [Abstract] [Full-text]
3. Parental lung cancer as predictor of cancer risks in offspring: clues about multiple routes of harmful influence?
   Int J Cancer, 118(3): 744-8. [Abstract] [Full-text]
4. An examination of characteristics of lung and colon cancer patients participating in a web-based decision support program. Internet-based decision support programs.
   Oncology, 69(4): 311-6. [Abstract] [Full-text]
5. A phase II study of the docetaxel-ifosfamide-carboplatin combination in advanced non-small-cell lung cancer.
   Oncology, 69(4): 333-41. [Abstract] [Full-text]
6. Paclitaxel, carboplatin and gemcitabine combination as induction chemotherapy for stage IIIA N2 bulky non-small cell lung cancer.
   Oncology, 69(4): 295-300. [Abstract] [Full-text]
7. Toll-like receptor 4 in butylated hydroxytoluene-induced mouse pulmonary inflammation and tumorigenesis.
   J Natl Cancer Inst, 97(23): 1778-81. [Abstract] [Full-text]
8. Levels of omega-3 fatty acid in serum phospholipids and depression in patients with lung cancer.
   Br J Cancer, 93(12): 1329-33. [Abstract] [Full-text]
9. HER3 genomic gain and sensitivity to gefitinib in advanced non-small-cell lung cancer patients.
   Br J Cancer, 93(12): 1334-40. [Abstract] [Full-text]
10. A phase I/II trial of irinotecan-cisplatin combined with an anti-late-diarrhoeal programme to evaluate the safety and antitumour response of this combination therapy in patients with advanced non-small-cell lung cancer.
    Br J Cancer, 93(12): 1341-9. [Abstract] [Full-text]
11. Induction of COX-2 protein expression by vanadate in A549 human lung carcinoma cell line through EGF receptor and p38 MAPK-mediated pathway.
    Biochem Biophys Res Commun, 339(2): 562-8. [Abstract] [Full-text]
12. ERK activation in arsenite-treated G1-enriched CL3 cells contributes to survival, DNA repair inhibition, and micronucleus formation.
    Toxicol Sci, 89(1): 164-72. [Abstract] [Full-text]
13. Expression of VDR and CYP24A1 mRNA in human tumors.
    Cancer Chemother Pharmacol, 57(2): 234-40. [Abstract] [Full-text]
14. Combination of topotecan and cisplatin in relapsed patients with small cell lung cancer: a phase II study of the hellenic cooperative oncology group (HeCOG).
    Cancer Chemother Pharmacol, 57(2): 207-12. [Abstract] [Full-text]
15. Phase II study of weekly irinotecan plus capecitabine for chemotherapy-naive patients with advanced nonsmall cell lung carcinoma.
    Cancer, 104(12): 2759-65. [Abstract] [Full-text]
16. Elderly subgroup analysis of a randomized phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for first-line treatment of advanced nonsmall cell lung carcinoma (TAX 326).
    Cancer, 104(12): 2766-74. [Abstract] [Full-text]
17. Does maintenance/consolidation chemotherapy have a role in the management of small cell lung cancer (SCLC)? A metaanalysis of the published controlled trials.
    Cancer, 104(12): 2650-7. [Abstract] [Full-text]
18. Drosophila caliban, a nuclear export mediator, can function as a tumor suppressor in human lung cancer cells.
    Oncogene, 24(56): 8229-39. [Abstract] [Full-text]
19. Enhancement of sensitivity to tumor necrosis factor alpha in non-small cell lung cancer cells with acquired resistance to gefitinib.
    Clin Cancer Res, 11(24): 8872-9. [Abstract] [Full-text]
20. Reveromycin A inhibits osteolytic bone metastasis of small-cell lung cancer cells, SBC-5, through an antiosteoclastic activity.
    Clin Cancer Res, 11(24): 8822-8. [Abstract] [Full-text]
21. Antitumor vascular strategy for controlling experimental metastatic spread of human small-cell lung cancer cells with ZD6474 in natural killer cell-depleted severe combined immunodeficient mice.
    Clin Cancer Res, 11(24): 8789-98. [Abstract] [Full-text]
22. Epithelial versus mesenchymal phenotype determines in vitro sensitivity and predicts clinical activity of erlotinib in lung cancer patients.
    Clin Cancer Res, 11(24): 8686-98. [Abstract] [Full-text]
23. Circulating aminopeptidase N/CD13 is an independent prognostic factor in patients with non-small cell lung cancer.
    Clin Cancer Res, 11(24): 8674-9. [Abstract] [Full-text]
24. Lung cancer risk and talc not containing asbestiform fibres: a review of the epidemiological evidence.
    Occup Environ Med, 63(1): 4-9. [Abstract] [Full-text]
25. Expression of telomeric repeat binding factor 1 in non-small cell lung cancer.
    J Surg Oncol, 93(1): 62-7. [Abstract] [Full-text]
26. Histone deacetylase inhibitor FR901228 enhances the antitumor effect of telomerase-specific replication-selective adenoviral agent OBP-301 in human lung cancer cells.
    Exp Cell Res, 312(3): 256-65. [Abstract] [Full-text]
27. Vault mobility depends in part on microtubules and vaults can be recruited to the nuclear envelope.
    Exp Cell Res, 312(3): 245-55. [Abstract] [Full-text]
28. Baseline chest radiograph for lung cancer detection in the randomized Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial.
    J Natl Cancer Inst, 97(24): 1832-9. [Abstract] [Full-text]
29. The prognostic significance of circulating neuroendocrine markers chromogranin a, pro-gastrin-releasing peptide and neuron-specific enolase in patients with advanced non-small-cell lung cancer.
    Tumour Biol, 27(1): 8-16. [Abstract] [Full-text]
30. Phase I and pharmacokinetic study of amrubicin, a synthetic 9-aminoanthracycline, in patients with refractory or relapsed lung cancer.
    Cancer Chemother Pharmacol, 57(3): 282-8. [Abstract] [Full-text]
31. Mdm2-mediated pRB downregulation is involved in carcinogenesis in a p53-independent manner.
    Biochem Biophys Res Commun, 340(1): 54-61. [Abstract] [Full-text]
32. Methylation profile in tumor and sputum samples of lung cancer patients detected by spiral computed tomography: a nested case-control study.
    Int J Cancer, 118(5): 1248-53. [Abstract] [Full-text]
33. Genetic variants in the MDM2 promoter and lung cancer risk in a Chinese population.
    Int J Cancer, 118(5): 1275-8. [Abstract] [Full-text]

© 2004-2008 Lung Cancer Research Today. All Rights Reserved.